The impact on clinical outcomes of post-operative radiation therapy delay after neoadjuvant chemotherapy in patients with breast cancer: A multicentric international study

Gustavo Nader Marta a, b, *, Reem AlBeesh c, Allan A. Lima Pereira d, Leandro Jonata Oliveira d, Max S. Mano d, Tarek Hijal c

a Department of Radiation Oncology — Hospital Sírio-Libanés, Sao Paulo, Brazil
b Department of Radiology and Oncology — Radiation Oncology Unit, Faculdade de Medicina da Universidade de São Paulo - Instituto Do Câncer Do Estado de São Paulo (ICESP), Sao Paulo, Brazil
c Division of Radiation Oncology, McGill University Health Centre, Montréal, Quebec, Canada
d Department of Clinical Oncology — Hospital Sírio-Libanés, Sao Paulo, Brazil

Keywords:
Breast cancer
Chemotherapy
Radiation therapy
Survival

Abstract

Introduction: Radiation therapy (RT) is frequently used for post-operative treatment in breast cancer (BC) patients who received preoperative systemic therapy (PST) and surgery. Nevertheless, the optimal timing to start RT is unclear.

Material and methods: Data from BC patients who underwent chemotherapy as PST, breast surgery and RT at 3 Institutions in Brazil and Canada from 2008 to 2014 were evaluated. Patients were classified into three groups regarding to the time to initiation of RT after surgery: <8 weeks, 8–16 weeks and >16 weeks.

Results: A total of 1029 women were included, most of them (59.1%; N = 608) had clinical stage III. One hundred and forty-one patients initiated RT within 8 weeks, 663 between 8 and 16 weeks and 225 beyond 16 weeks from surgery. With a median follow-up of 32 months, no differences in disease-free survival (DFS), overall survival and locoregional recurrence-free survival (LRRFS) were observed of time to indicated RT (<8 weeks versus 8–16 weeks versus >16 weeks). However, in luminal subtype patients (46.5%; N = 478), initiation of RT up to 8 weeks after surgery was associated with better LRRFS (<8 weeks versus >16 weeks: HR 0.22; 95%CI 0.05–0.86; p = 0.03), with a tendency to a better DFS (<8 weeks versus >16 weeks: HR 0.50; 95%CI 0.25–1.00).

Conclusion: RT initiated up to 8 weeks after surgery was related to better LRRFS in luminal BC patients who underwent PST. Our results suggest that early start of RT is important for these patients.

© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Worldwide, breast cancer (BC) is one of the most prevalent tumors among women [1]. A multidisciplinary management is essential to achieve the curative treatment [2]. This comprises synchronized and timely approach of breast surgery, systemic therapy, and post-operative radiation therapy (RT).

Based on phase III trials, RT after both mastectomy and breast conserving surgery (BCS) improves local control and survival rates for most patients with BC. Nonetheless, none of these trials comprised patients that received chemotherapy as preoperative systemic therapy (PST) [3–5]. The role of RT in BC patients treated with PST has been established mostly based on retrospective data. These studies showed a solid rationale for the use of RT to the breast/chest wall and regional nodes for locally advanced BC women. Moreover, in a subgroup of stage II disease with high-risk for loco-regional relapse, RT was associated with better clinical outcomes [6–15].

In clinical practice, the indication of RT in BC patients treated
with PST is normally guided by pre-PST tumors’ and patients’ characteristics, the type of surgery performed, as well as the response of the tumor to treatment [16–18].

Timely initiation of oncology treatments has been a problem due to economic limitations and/or overloaded medical centers, especially in developing countries and in welfare states with public health systems [19–21]. Of note, it has been demonstrated that time to initiation post-operative chemotherapy significantly impacts survival rates [22,23]. Nevertheless, the clinical influence of delayed RT is uncertain, as previous reports generated conflicting results [24–27].

We have previously reported on our experience which suggested that delayed administration of RT after PST was associated with worse clinical outcomes. However, the sample employed in that study had a potential bias which was the small number of patients treated with RT within 8 weeks from surgery, resulting in large confidence intervals [24].

The aim of this study was to assess the potential impact of the time to start of RT in patients with BC who received PST and breast surgery in a larger and more diversified (multinational cohort) patient population.

1.1. Patients and methods

This is a multicentric retrospective study that included BC patients who underwent chemotherapy as PST followed by breast surgery and RT at Instituto do Câncer do Estado de São Paulo (ICESP) — a public institution from Brazil, Hospital Sírio-Libanès — a private institution from Brazil, and McGill University Health Center (MUHC) — Canada. Data were consecutively collected in the 3 hospitals from 2008 to 2014. The electronic charts were assessed to obtain data on demographic, tumor and treatment features of all patients. All patients received RT in the breast or chest wall with or without regional nodal irradiation.

Patients were classified into three groups regarding to the time to initiation of RT after surgery: <8 weeks, 8–16 weeks, and >16 weeks.

The primary endpoint was disease-free survival (DFS) defined as

Table 1
Patient and clinical features.

| Characteristics                        | <8 weeks (N = 141) | 8–16 weeks (N = 663) | >16 weeks (N = 225) |
|----------------------------------------|-------------------|----------------------|---------------------|
| Clinical stage*                        |                   |                      |                     |
| I                                      | 6 (4.3%)          | 14 (2.1%)            | 3 (1.3%)            |
| II                                     | 64 (45.4%)        | 262 (39.5%)          | 60 (26.7%)          |
| III                                    | 68 (48.2%)        | 380 (57.3%)          | 169 (71.1%)         |
| Missing                                | 3 (2.1%)          | 7 (1.1%)             | 2 (0.9%)            |
| Hitological grade                      |                   |                      |                     |
| 1                                      | 14 (9.9%)         | 33 (5.0%)            | 14 (6.2%)           |
| 2                                      | 56 (39.7%)        | 287 (43.3%)          | 103 (45.8%)         |
| 3                                      | 65 (46.1%)        | 334 (50.4%)          | 105 (46.7%)         |
| Missing                                | 6 (4.3%)          | 5 (0.8%)             | 0 (0.0%)            |
| Hormonal and Her2 status               |                   |                      |                     |
| HRpos Her2 neg (luminal)               | 76 (53.9%)        | 297 (44.8%)          | 105 (46.7%)         |
| HR neg Her2 pos                        | 29 (20.6%)        | 128 (19.3%)          | 35 (15.6%)          |
| HRneg Her2 neg(triple negative)        | 11 (7.8%)         | 40 (6.0%)            | 9 (4.0%)            |
| Missing                                | 6 (4.3%)          | 5 (0.8%)             | 0 (0.0%)            |
| Primary systemic therapy               |                   |                      |                     |
| Anthracycline-taxane                   | 126 (89.4%)       | 606 (91.4%)          | 205 (91.1%)         |
| Others                                 | 13 (9.2%)         | 50 (7.5%)            | 19 (8.4%)           |
| Missing                                | 2 (1.4%)          | 7 (1.1%)             | 1 (0.4%)            |
| Trastuzumab in Her2 + (N = 252)        |                   |                      |                     |
| Yes                                    | 39 (97.5%)        | 163 (97.0%)          | 41 (93.2%)          |
| No                                     | 1 (2.5%)          | 2 (1.2%)             | 2 (4.5%)            |
| Missing                                | 0 (0.0%)          | 3 (1.8%)             | 1 (2.3%)            |
| Pertuzumab in Her2 + (N = 252)         |                   |                      |                     |
| Yes                                    | 4 (10.0%)         | 1 (0.6%)             | 1 (2.3%)            |
| No                                     | 36 (90.0%)        | 165 (98.2%)          | 42 (95.5%)          |
| Missing                                | 0 (0.0%)          | 2 (1.2%)             | 1 (2.3%)            |
| Endocrine therapy in HR-positive (N = 680) |                   |                      |                     |
| Yes                                    | 99 (98.3%)        | 415 (95.8%)          | 137 (97.2%)         |
| No                                     | 5 (4.7%)          | 13 (3.0%)            | 3 (2.1%)            |
| Missing                                | 2 (1.9%)          | 5 (1.2%)             | 1 (0.7%)            |
| Surgery                                |                   |                      |                     |
| Mastectomy                             | 76 (51.9%)        | 441 (66.5%)          | 179 (79.6%)         |
| BCS                                    | 65 (46.1%)        | 221 (33.3%)          | 46 (20.4%)          |
| Missing                                | 0 (0.0%)          | 1 (0.2%)             | 0 (0.0%)            |
| Axillary dissection                    |                   |                      |                     |
| Yes                                    | 103 (73.0%)       | 516 (77.8%)          | 200 (88.9%)         |
| No                                     | 38 (27.0%)        | 144 (21.7%)          | 23 (10.2%)          |
| Missing                                | 0 (0.0%)          | 3 (0.5%)             | 2 (0.9%)            |
| pCR                                    |                   |                      |                     |
| Yes                                    | 28 (19.9%)        | 142 (21.4%)          | 38 (16.9%)          |
| No                                     | 113 (80.1%)       | 520 (78.4%)          | 187 (83.1%)         |
| Missing                                | 0 (0.0%)          | 1 (0.2%)             | 0 (0.0%)            |

Note: HR, hormone receptor; HER2, human epidermal growth factor receptor 2; pCR, pathologic complete response; BCS, breast conserving surgery; pos, positive; neg, negative *clinical stage according to AJCC 2010.
the time from date of surgery to the date of relapse at any site or death from any cause. Secondary endpoints were overall survival (OS), defined as the time from date of surgery to death from any cause, locoregional recurrence-free survival (LRRFS), defined as the time from date of surgery to local and/or regional recurrence, and distant-recurrence free survival, defined as the time from date of surgery to distant recurrence.

Pathological complete response (pCR) is defined as the absence of residual invasive carcinoma (ypT0pN0 or ypTisN0).

The patients’ follow-up was performed by history and physical examination: every 3–4 months for 1–2 years, then every 6 months for 5 years, and then annually. Bilateral breast mammograms were performed annually. In the presence of clinical signs and symptoms suggestive of recurrent disease, additional exams (laboratory and/or imaging studies) for screening were performed.

1.2. Statistical methods

Patients were categorized according to the time (in weeks) from definitive surgery to RT into one of three groups: <8 weeks, 8–16 weeks, and >16 weeks. Demographics and baseline characteristics were summarized using descriptive statistics and compared using ANOVA, Kruskal-Wallis test for continuous variables and Fisher’s exact test or c2-test for categorical variables, whenever appropriate. OS and DFS curves were estimated with the Kaplan-Meier method and compared them with the log-rank. We used Cox proportional hazard regression models to estimate hazard ratios (HRs) and to investigate whether the effect of time to receive RT was modified by adjustments for the following covariates: age (as continuous variable), subtype, type of surgery, pCR, and institution.

2. Results

2.1. Patients characteristics

A total of 1029 patients were included, with a median follow-up of 32 months (range: 1–124). A total of 581 patients (56.5%) were from ICESP, 376 (36.5%) from HSL and 72 (7%) from the MUHC. Although most patients (59.8%; N = 615) had locally advance clinical stage III disease, the groups were unbalanced in terms of...
disease stage, with a higher proportion of stage III patients in the >16-week group (Table 1). Anthracycline and taxane-based PST was used for most patients (91.1%; N = 937), and the majority were treated with a mastectomy (67.6%; N = 696). Almost all estrogen and/or progesterone receptor positive patients received endocrine therapy (96.9%; N = 651) in adjuvant setting, and almost all (96.4%; N = 243) HER-2 positive patients received trastuzumab with or without pertuzumab in both neoadjuvant and adjuvant settings (Table 1).

The most usual RT schedule was the conventional 50Gy–50.4Gy in 25–28 fractions (82.3%; N = 847). Hypofractionated irradiation with doses of 40.05Gy–42.5Gy delivered in 15–16 fractions was used in 42% of patients. Most patients received regional nodal irradiation (81.6% to the supraclavicular fossa; 76.0% to the axillary levels 2 and 3; 43.8% to the axillary level 1; 13.7% to the internal mammary).

The median time to initiation of RT was 11 weeks. One hundred and forty-one (13.7%) patients received RT < 8 weeks from surgery, 663 (64.4%) 8–16 weeks and 225 (21.9%) > 16 weeks from surgery.

2.2. Survival outcomes

A total of 92 (8.9%) patients had locoregional recurrence, 232 (22.5%) distant recurrence, and 252 (24.5%) locoregional and/or distant recurrence events.

In the overall patient population, no differences in terms of DFS, OS and LRRFS were observed according to the time of initiation of RT (<8 weeks versus 8–16 weeks versus >16 weeks) - Fig. 1.

Fig. 2 depicts DFS rates for the various molecular sub-types (luminal, triple positive, Her-2 pure and triple negative) according to time of initiation of RT. For luminal sub-type patients (46.5%; N = 478), starting RT within 8 weeks significantly improved DFS (log-rank p 0.037 - Fig. 2).

Moreover, for this group of patients, LRRFS and distant disease-free survival (DDFS) were also improved in patients who started RT within 8 weeks, though with no differences in OS rates (Fig. 3).

As an exploratory analysis, we estimated adjusted HRs for survival endpoints (DFS, LRRFS and DDFS) for luminal patients by time to initiation of RT according to the following subgroups: pCR, institution, age, type of surgery and stage. The results after adjusting for confounders are presented in supplement 1. Comparing to patients who started RT after 8 weeks from surgery, a better LRRFS and DDFS favoring treatment within 8 weeks was found.

3. Discussion

This multicentric, multinational study is the largest so far...
addressing the clinical impact of timing to start RT in BC patients treated with PST and surgery. Our cohort comprised mostly of patients with locally advanced disease who were homogeneously treated with standard systemic therapy. In this context, in which RT is recognized to be related to improved local and survival rates [3,4], our results suggest that RT started >8 weeks from surgery was not related to poorer clinical outcomes in the overall study population.

Previous reports [25,26,28] evaluated timing of RT in early BC patients who underwent breast conservative surgery with adjuvant systemic therapy (which might have worked as a protector effect between RT and, hypothetically decreasing any deleterious consequence of delaying RT treatment). The first report of our group that included data from one single Brazilian Public Center showed a statically significant benefit in OS and DFS to initiate RT <8 weeks [24]. However, as previously noted, this group was very small and potentially not well representative of the full population. To minimize to possible bias of the single center analyzes, we performed the present study comprising data from three Oncology Centers (Brazil – Public Center; Brazil – Private Center; Canada). We assessed the timing of RT initiation in a homogeneous group of patients, be likely to harbor more advanced disease, theoretically assigning them at higher risk from RT delays. After an evaluation of more than 1000 patients, we found no clear relationship between the time to start RT and oncological outcomes. Similarly with our findings, a retrospective study reported on 248 patients across different time-points who underwent RT, did not find significant differences in locoregional outcome among the three groups of patients [8 weeks vs. >8 weeks (p = 0.634), <12 vs >12 weeks (p = 0.332), or <16 vs >16 weeks (p = 0.549)], supporting the theory that RT should be offered regardless of the time elapsed since the last treatment [27]. However, in our study, in the subgroup of luminal patients, the early start of RT was associated with improvement in DFS, LRRFS and DDFS. This result can be potentially explained by the fact that luminal tumors are the group that least responds to systemic treatment, implying that the more chemosensitive Her2+ and TN patients were better “protected” by chemotherapy ± anti-Her2 therapy against loco-regional failure making the clinical impact of delaying RT less relevant in these subgroups. Despite the better overall prognosis of luminal breast cancer compared to the other molecular subtypes (Her+, triple negative) [29], it is possible to infer that shorter time of RT may benefit luminal BC patients.

Our study has limitations which may have influenced the results. First, it is retrospective in nature, making it more be vulnerable to errors such as selection bias. Second, the short median follow-up time, which is a problem particularly for luminal BC patients, who are more likely to present late tumor relapse. Thus, these limitations represent weaknesses within the study that may influence outcomes and conclusions of the research, being a fact.
that may restrict the application of the study findings in clinical practice.

They are the constraints on generalizability, applications to practice, and/or utility of findings that are the result of the ways in which you initially chose to design the study or the method used to establish internal and external validity or the result of unanticipated challenges that emerged during the study.

In conclusion, RT initiated up to 8 weeks after surgery was related to better LRRFS in luminal BC patients who underwent PST. Our results suggest that early start of RT, within 8 weeks of surgery, is important for these patients.

Financial support

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

All authors declare that they have no conflicts of interest in relation to the authorship or publication of this contribution.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.breast.2020.08.013.

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLO- BOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA – Cancer J Clin 2018;68:394–424.
[2] Kessom EM, Allardice GM, George WD, et al. Effects of multidisciplinary team working on breast cancer survival: prospective, comparative, interventional cohort study of 13,722 women. BMJ 2012;344:e2718.
[3] Early Breast Cancer Trialists’ Collaborative G, Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378:1707–16.
[4] Echtgen, Mcalep P, Taylor C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383:2127–35.
[5] Marta GN, de Moraes P. Postoperative nodal irradiation in breast cancer patients with 1 to 3 axillary lymph nodes involved: the debate continues. Expert Rev Anticancer Ther 2015;15:1257–9.
[6] Akay CL, Meric-Bernstam F, Hunt KK, et al. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2012;79:901–7.
[7] Buchholz TA, Katz A, Strom EA, et al. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2002;52:880–8.
[8] Buchholz TA, Tucker SL, Masullo L, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 2002;20:17–23.
[9] Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 2004;22:2303–12.
[10] Garg AK, Oh JH, Oswald MJ, et al. Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys 2007;69:1478–83.
[11] Huang EH, Strom EA, Perkins GH, et al. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys 2006;66:352–7.
[12] Huang EH, Tucker SL, Strom EA, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004;22:4691–9.
[13] McGuire SE, Gonzalez-Angulo AM, Huang EH, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2007;68:1004–9.
[14] Rusthoven CG, Rabinovitch RA, Jones BL, et al. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis. Ann Oncol 2016;27:818–27.
[15] Kantor O, Pesce C, Singh P, et al. Post-mastectomy radiation therapy and overall survival after neoadjuvant chemotherapy. J Surg Oncol 2017.
[16] Lima K, Pereira AAL, de Freitas TB, et al. Patterns of post-operative irradiation in breast cancer patients submitted to neoadjuvant chemotherapy. Rep Pract Oncol Radiother 2019;24:115–23.
[17] Mamounas EP, Anderson SJ, Dignam J, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and 8-27. J Clin Oncol 2012;30:3960–6.
[18] Fowble BL, Einck JP, Kim DN, et al. Role of postmastectomy radiation therapy in low-income and middle-income countries. Lancet Oncol 2006;7:584–95.
[19] Elmore SN, Sethi RV, Kavuma A, et al. Broken machines or broken systems: the road to meaningful global radiotherapy access. J Glob Oncol 2017;3:438–40.
[20] Yap ML, Hanna TP, Shafig J, et al. The benefits of providing external beam radiotherapy in low- and middle-income countries. Clin Oncol 2017;29:72–83.
[21] Chavez-MacGregor M, Clarke CA, Lichtensztajn D, et al. Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol 2016;2:322–9.
[22] Gagliano Dde M, Gonzalez-Angulo AM, Lei X, et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 2014;32:735–44.
[23] Silva SB, Pereira AAL, Marta GN, et al. Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer. Breast 2018;38:39–45.
[24] Jobsen JJ, van der Palen J, Baum M, et al. Timing of radiotherapy in breast-conserving therapy: a large prospective cohort study of node-negative breast cancer patients without adjuvant systemic therapy. Br J Canc 2013;108:820–5.
[25] Vujovic O, Yu E, Cherian A, et al. Eleven-year follow-up results in the delay of breast irradiation after conservative breast surgery in node-negative breast cancer patients. Int J Radiat Oncol Biol Phys 2006;64:760–4.
[26] Desai S, Hurley J, Takita C, et al. Impact of surgery–radiation interval on locoregional outcome in patients receiving neo-adjuvant therapy and mastectomy. Breast J 2013;19:427–30.
[27] Hebert-Croteau N, Freeman CR, Latreille J, et al. A population-based study of the impact of delaying radiotherapy after conservative surgery for breast cancer. Breast Canc Res Treat 2004;88:187–96.
[28] Berruti A, Amoroso V, Gallo F, et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol 2014;32:3833–91.